Heminevrin

Heminevrin is a prescription medication that contains the active ingredient clomethiazole. It is supplied as an oral formulation, though specific strength details are not disclosed. Classified as a sedative‑hypnotic, Heminevrin acts on the central nervous system and is used in the European market for managing conditions related to alcohol withdrawal and insomnia.

Heminevrin is indicated for short‑term management of symptoms associated with alcohol withdrawal and for occasional insomnia when other treatments are unsuitable.

- Treatment of acute alcohol withdrawal syndrome under medical supervision. - Short‑term relief of insomnia in patients requiring a sedative‑hypnotic. - Adjunct therapy in hospital settings for patients at risk of severe withdrawal complications. - Use in controlled environments where monitoring of respiratory function is possible. - May be considered when benzodiazepines are contraindicated or ineffective.

Clomethiazole can produce a range of neurological and systemic effects, some of which are expected and others that require medical attention.

Common: - Drowsiness or sedation. - Dizziness or light‑headed feeling. - Headache. - Nausea or mild gastrointestinal upset. - Dry mouth. - Transient visual disturbances.

Serious: - Respiratory depression, especially when combined with other depressants. - Severe hypotension or cardiovascular instability. - Paradoxical agitation or confusion. - Allergic reactions such as rash, itching, or swelling. - Hepatic dysfunction indicated by jaundice or elevated liver enzymes. - Seizures in patients with abrupt discontinuation.

When prescribing Heminevrin, clinicians should evaluate patient history and monitor for potential complications.

- Assess respiratory function before initiation, particularly in patients with chronic lung disease. - Use the lowest effective dose for the shortest duration to reduce dependence risk. - Avoid use in patients with severe hepatic impairment. - Caution in the elderly due to increased sensitivity to sedative effects. - Monitor for signs of withdrawal if therapy is discontinued abruptly. - Evaluate for concomitant use of other central nervous system depressants. - Discuss potential effects on psychomotor performance and advise against operating machinery.

Clomethiazole may interact with several drug classes, altering its efficacy or safety profile.

Avoid: - Other CNS depressants (e.g., benzodiazepines, opioids, barbiturates) due to additive respiratory depression. - Alcohol, which can potentiate sedative effects and increase overdose risk. - Strong CYP3A4 inhibitors that may raise clomethiazole plasma levels.

Use with caution: - CYP3A4 inducers that could reduce therapeutic effect. - Antidepressants, particularly SSRIs, which may increase the risk of serotonin syndrome. - Antihistamines and antihypertensives that can enhance sedation or hypotension. - Medications affecting hepatic metabolism, requiring dose adjustments or closer monitoring.